Problems with constructing tests to accept the null hypothesis

Springer Proceedings in Mathematics and Statistics

Volumn 118, Issue , 2015, Pages 49-54

  Rogatko, André ^a   Piantadosi, Steven ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCEPTANCE TESTS;

ALTERNATIVE HYPOTHESIS; ASSOCIATED TYPES; BAYESIAN; CONVENTIONAL METHODS; HYPOTHESIS TESTS; NULL HYPOTHESIS; TYPE I AND II ERRORS;

STATISTICAL TESTS;

EID: 84924034345     PISSN: 21941009     EISSN: 21941017     Source Type: Conference Proceeding    
DOI: 10.1007/978-3-319-12454-4_4     Document Type: Conference Paper

References (16)

1. Palesch, Y. Y., Tilley B. C.: An efficient multi-stage, single-arm Phase II futility design for ALS. Amyotroph. Later. Scler. Other Mot. Neuron Disord. 5, 55-56 (2004).
2. Elm, J. J., Goetz, C. G., Ravina, B., Shannon, K., Wooten, G. F., Tanner, C. M., et al.: A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann. Neurol. 57, 197-203 (2005).
3. Levin, B.: The utility of futility. Stroke 36, 2331 (2005).
4. Palesch, Y. Y., Tilley, B. C., Sackett, D. L., Johnston, K. C., Woolson, R.: Applying a phase II futility study design to therapeutic stroke trials. Stroke 36, 2410 (2005).
5. Levin, B.: Selection and futility designs. In: Ravina, B., Cummings, J., McDermott, M., Poole, R. M. (eds.) Clinical Trials in Neurology: Design, Conduct, Analysis, pp. 78-90. Cambridge University Press, Cambridge (2012).
6. Wellek, S.: Testing Statistical Hypotheses of Equivalence and Noninferiority, 2nd edn. Chapman & Hall/CRC, Boca Raton. (2010).
7. Neyman, J.: On the problem of the most efficient tests of statistical hypotheses. Philos. Trans. Royal Soc. Lond. Ser. A Contain. Pap. Math. Phys. Charact. 231, 289-337 (1933).
8. Gehan, E. A.: Determination of number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J. Chron. Dis. 13, 346 (1961).
9. Simon, R.: Optimal 2-stage designs for phase-II clinical-trials. Controll. Clin. Tr. 10, 1-10 (1989).
10. Aberson, C.: Interpreting null results: improving presentation and conclusions with confidence intervals. J. Artic. Support Null Hypothesis 1, 36 (2002).
11. Altman, D. G., Bland, J. M.: Statistics notes: absence of evidence is not evidence of absence. BMJ 311, 485 (1995).
12. Kieburtz, K., Tilley, B., Ravina, B., Galpern, W., Shannon, K., Tanner, C., et al.: A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin. Neuropharmacol. 31, 141 (2008).
13. Dunnett, C. W., Gent, M.: Significance testing to establish equivalence between treatments, with special reference to data in form of 2 x 2 tables. Biometrics 33, 593-602 (1977).
14. Blackwelder, W. C.: Proving the null hypothesis in clinical-trials. Controll. Clin. Tr. 3, 345 (1982).
15. Royall, R. M.: Statistical Evidence: A Likelihood Paradigm. Chapman & Hall, Boca Raton (1997).
16. Rogatko, A., Litwin, S.: Phase II studies: which is worse, false positive or false negative? J. Natl. Cancer Inst. 88, 461 (1996).